Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Although tyrosine kinase inhibitors (TKIs) are effective in treating chronic myeloid leukemia (CML), they often fail to eradicate the leukemia-initiating stem cells (LSCs), causing disease persistence and relapse. Evidence indicates that LSC persistence may be because of bone marrow (BM) niche prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolinska, Monika, Cai, Huan, Månsson, Alma, Shen, Jingyi, Xiao, Pingnan, Bouderlique, Thibault, Li, Xidan, Leonard, Elory, Chang, Marcus, Gao, Yuchen, Medina, Juan Pablo, Kondo, Makoto, Sandhow, Lakshmi, Johansson, Anne-Sofie, Deneberg, Stefan, Söderlund, Stina, Jädersten, Martin, Ungerstedt, Johanna, Tobiasson, Magnus, Östman, Arne, Mustjoki, Satu, Stenke, Leif, Le Blanc, Katarina, Hellström-Lindberg, Eva, Lehmann, Sören, Ekblom, Marja, Olsson-Strömberg, Ulla, Sigvardsson, Mikael, Qian, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651879/
https://www.ncbi.nlm.nih.gov/pubmed/37018663
http://dx.doi.org/10.1182/blood.2022016896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651879/
https://www.ncbi.nlm.nih.gov/pubmed/37018663
http://dx.doi.org/10.1182/blood.2022016896

Ejemplares similares